11/19
05:41 pm
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $39.00 price target on the stock.
Medium
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $39.00 price target on the stock.
11/19
02:49 pm
rckt
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst [Yahoo! Finance]
Low
Report
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst [Yahoo! Finance]
11/19
11:09 am
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its price target lowered by analysts at Leerink Partners from $46.00 to $44.00. They now have an "outperform" rating on the stock.
Low
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its price target lowered by analysts at Leerink Partners from $46.00 to $44.00. They now have an "outperform" rating on the stock.
11/19
09:31 am
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Medium
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
11/19
08:20 am
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $52.00 price target on the stock.
Medium
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $52.00 price target on the stock.
11/19
08:20 am
rckt
2024 BioTech Breakthrough Awards Program Celebrates Groundbreaking Biotechnology Innovators Around the World [Yahoo! Finance]
Medium
Report
2024 BioTech Breakthrough Awards Program Celebrates Groundbreaking Biotechnology Innovators Around the World [Yahoo! Finance]
11/18
07:40 pm
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $62.00 price target on the stock.
Medium
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $62.00 price target on the stock.
11/18
11:06 am
rckt
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference [Yahoo! Finance]
Low
Report
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference [Yahoo! Finance]
11/18
11:00 am
rckt
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
Low
Report
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
11/12
04:41 pm
rckt
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions [Yahoo! Finance]
Low
Report
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions [Yahoo! Finance]
11/12
04:01 pm
rckt
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions
Medium
Report
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions
11/11
04:56 pm
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $62.00 price target on the stock.
Medium
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $62.00 price target on the stock.
11/11
11:49 am
rckt
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus [Yahoo! Finance]
Medium
Report
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus [Yahoo! Finance]
11/8
08:46 am
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $52.00 price target on the stock.
Medium
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $52.00 price target on the stock.
11/8
07:00 am
rckt
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
Low
Report
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
11/7
04:18 pm
rckt
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress [Yahoo! Finance]
Medium
Report
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress [Yahoo! Finance]
11/7
04:01 pm
rckt
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
Low
Report
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
11/7
07:10 am
rckt
Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation [Yahoo! Finance]
10/16
08:44 am
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Medium
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
9/30
12:18 pm
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $38.00 price target on the stock.
Low
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $38.00 price target on the stock.
9/30
05:46 am
rckt
Arrhythmogenic Cardiomyopathy (ACM) Market Research Report 2024: US and EU5 Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access [Yahoo! Finance]
Low
Report
Arrhythmogenic Cardiomyopathy (ACM) Market Research Report 2024: US and EU5 Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access [Yahoo! Finance]
9/17
11:11 am
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $52.00 price target on the stock.
Low
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $52.00 price target on the stock.
9/17
07:00 am
rckt
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
Medium
Report
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
9/10
07:00 am
rckt
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
Low
Report
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
9/9
01:04 pm
rckt
Rocket Stock Down More Than 30% in Past Six Months: Here's Why [Yahoo! Finance]
Low
Report
Rocket Stock Down More Than 30% in Past Six Months: Here's Why [Yahoo! Finance]